Author

CR Libertin

Observed name: C.R. Libertin

Institution: Mayo Clinic in Florida

Observed institution: Mayo Clinic in Florida

OpenAlex ID: A5064835623

S48 Lenzilumab efficacy and safety in newly hospitalized Covid-19 subjects: results from the LIVE-AIR phase 3 randomized double-blind placebo-controlled trial

2021 · Z Temesgen, CD Burger, et al. · 2

Assessing Critical Resources: Early Estimation of Mechanical Ventilation and Extracorporeal Mechanical Oxygenation in COVID-19 Patients Based on Early Immune WBC Differential Profiles

2023 · S. Isha, C.R. Libertin, et al.

S49 C-reactive protein as a biomarker for improved efficacy of lenzilumab in Covid-19 patients: results from the LIVE-AIR trial

2021 · Z Temesgen, CD Burger, et al.

Works count: 3

Citation count: 2

H-index: 1

I10-index: